Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor

BACKGROUND: Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but have received little attention. The drugs, pembrolizumab and nivolumab are recently approved inhibitors of the PD-1 receptor that have overlapping AE profiles...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Cancer
Auteurs principaux: Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D., Lacouture, M.E.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4998047/
https://ncbi.nlm.nih.gov/pubmed/27043866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2016.02.010
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires